Drug discovery platform: HUB Organoids serve as an ideal platform for drug discovery screening, target discovery, and genomic and functional studies on a scale that could never be achieved for clinically relevant models.
Drug development: HUB Organoids provide drug efficacy, safety and mechanistic data. Furthermore, disease-specific collections of organoids enable pre-clinical stratification of patient populations.
During clinical trials of new treatments carried out by the pharma industry, it is almost always unclear why an individual patient responds or doesn’t respond to the treatment. It is only when very specific biomarkers are known that we have an indication of why treatments are successful or not. Organoids can serve as the ultimate biomarker because they can be generated from each patient in the trial. In vitro tests on these patient organoids will demonstrate if the lab response correlates to the clinical response, successful or not. The organoid therefore serves as a tool for identifying the mechanism underlying success and failure and/or serves as a companion diagnostic in the event that the treatment is successful.
HUB has created an organoid biobank from patient material that captures disease heterogeneity in diseases such as cancer, cystic fibrosis and IBD. The biobank is an expanding resource of highly characterised organoids for different organ systems and includes both the genetic and clinical data of the patient.
The clinical application of HUB Organoids by generating organoids from individual patients provides a next generation tool for predictive diagnostics, designing targeted and personalised therapies as well as clinical patient stratification.
Animal Derived Organoids
Organoids derived from mice, rats, dogs, and mini pigs allow for in vitro toxicology and research that will provide high throughput whilst maintaining in vivo relevance. In addition to providing a direct comparison between animal and human studies it will help decrease the use of animals in medical research.